Bioequivalence and Bioavailability Forum 06:39 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Multiple Dose, Steady State-Partial reference replicate [Design Issues]

posted by ElMaestro - Denmark, 2018-07-13 13:42  - Posting: # 19047
Views: 750

Hi arl_stat,

» Please help in understanding whether it is possible to conduct “An open-label, randomized, Multiple Dose, Steady State, two treatments, three periods, three sequence, three way, Reference Replicated crossover bioequivalence study” for USFDA Submission?

Yes to everything except (conditionally) the term 'three way' in the context of your post.

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,882 posts in 4,026 threads, 1,271 registered users;
online 4 (0 registered, 4 guests [including 4 identified bots]).

Some scientists claim that hydrogen, because it is so plentiful,
is the basic building block of the universe.
I dispute that. I say there is more stupidity than hydrogen,
and that is the basic building block of the universe.    Frank Zappa

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed